TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15829494
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) + Cisplatin (CDDP) 200 mg/m² daily on days 1-5 and 75 mg/m² of CDDP on day 1
Study: 2586199
Drug: Tamoplex 10
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoplex 10 mg
Study: 2586199
Drug: Nolvadex 10
Normalized name: Nolvadex 10mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nolvadex 10 mg
Study: 31314107
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy (n = 120)
Study: 31314107
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (n = 127)
Study: 28189417
Drug: Nomogram-based FSH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nomogram-based FSH starting dose (based on multiple biomarkers)
Study: 28189417
Drug: Age-based FSH
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age-based FSH starting dose (150 IU if ≤35 years, 225 IU if >35 years)
Study: 25384017
Drug: Depression CAREPATH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depression CAREPATH intervention (nurses managing depression at routine home visits with weekly symptom assessment, medication management, care coordination, education, and goal setting)
Study: 23211762
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (20 mg L and 2 mg Z)
Study: 23211762
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (10 mg L, 2 mg Z and 10 mg MZ)
Study: 23211762
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (3 mg L, 2 mg Z and 17 mg MZ)
Study: 21560845
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose I-131 treatment (150 microCi/gm, initial mean activity 10.2 mCi)
Study: 21560845
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose I-131 treatment (100 microCi/gm, initial mean activity 8 mCi)
Study: 21560845
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose I-131 treatment
Study: 21560845
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose I-131 treatment
Study: 9476493
Drug: Topical bifonazole
Normalized name: bifonazole Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bifonazole (Mycospor Solution) alone (group I)
Study: 9476493
Drug: Topical bifonazole
Normalized name: bifonazole Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bifonazole (Mycospor Solution) plus 10% urea ointment (Urepearl) (group II)
Study: 3627208
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of oral corticosteroids (methylprednisolone, 32 mg) approximately 12 hours and 2 hours before challenge with contrast material
Study: 23701339
Drug: Propofol with
Normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol with alfentanil (10 μg/kg alfentanil followed by 1 mg/kg propofol, followed by 0.5 mg/kg every 3 minutes as needed)
Study: 23701339
Drug: Propofol only
Normalized name: Propofol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol only (1 mg/kg propofol, followed by 0.5 mg/kg every 3 minutes as needed)
Study: 20963671
Drug: Internet-assisted aftercare
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-assisted aftercare group treatment
Study: 17846859
Drug: HRT (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (oral, transdermal, intranasal)
Study: 12801957
Drug: Open label
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label infliximab (10 mg/kg)
Study: 11199363
Drug: White wine
Normalized name: White wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: White wine (300 ml, 8% vol/vol)
Study: 11199363
Drug: Ethanol solution
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethanol solution (8% vol/vol)
Study: 11199363
Drug: Wet swallow
Normalized name: DRESSING,WET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet swallow (5 ml)
Study: 11199363
Drug: All beverages
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All beverages (White wine, Ethanol solution, Tap water)
Study: 3901244
Drug: MOCCA chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOCCA chemotherapy regimen (vincristine, methylprednisolone, and 3 alkylating agents)
Study: 3901244
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further chemotherapy after 12 months
Study: 16003672
Drug: Warm-water therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm-water therapy (40 degrees C)
Study: 16003672
Drug: Cold-water therapy
Normalized name: Anbesol Cold Sore Therapy
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-water therapy (13 degrees C)
Study: 8717309
Drug: Steroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid therapy (prednisolone 20‐60 mg/day orally, or pulse therapy)
Study: 1908630
Drug: Slow-release nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release nifedipine (20 mg at 10 P.M. or 2 doses of 20 mg at 10 P.M. and 6 A.M.)
Study: 6815153
Drug: Incentive +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incentive + problem-solve procedure (combination of incentive and problem-solve techniques)
Study: 31721914
Drug: Antibiotic in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic in the diet (0.01 g kg‐1)
Study: 31721914
Drug: Antibiotic in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic in the water (0.002 g L‐1)
Study: 31721914
Drug: Commercial probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial probiotic (Saccharomyces cerevisiae) in the diet (1 g Kg‐1)
Study: 31721914
Drug: Antibiotic in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic in the water and yeast in the diet (0.002 g L‐1 and 1 g Kg‐1)
Study: 31721914
Drug: Yeast in
Normalized name: Bakers Yeast Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast in the diet (1 g Kg‐1)
Study: 24923259
Drug: ACT (Acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT (Acceptance and Commitment Therapy)
Study: 19108951
Drug: MDT (Multidisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDT (Multidisciplinary Treatment)
Study: 16574123
Drug: Peripheral intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous cannulas re‐sited only when complications occurred
Study: 16574123
Drug: Peripheral intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous cannulas re‐sited every 3 days
Study: 15475527
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dichloroacetate (DCA) infusion during rhythmic handgrip (RHG) exercise
Study: 15881488
Drug: Pioglitazone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone plus metformin
Study: 2404805
Drug: Gestrinone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone 1.25 mg twice weekly (group I)
Study: 2404805
Drug: Gestrinone 2.5
Normalized name: gestrinone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestrinone 2.5 mg twice weekly (group II)
Study: 2404805
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of gestrinone
Study: 30570303
Drug: Dissonance-based Body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dissonance-based Body Project treatment (BPT)
Study: 30570303
Drug: Supportive mindfulness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive mindfulness treatment
Study: 28265678
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg daily for 4 weeks
Study: 19179916
Drug: Daily walks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily walks
Study: 11852293
Drug: Theophylline (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (10-20 microg/mL after 15 days of treatment)
Study: 31502676
Drug: Original method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original method for generating null distributions of statistics pertaining to differences in G matrices
Study: 31502676
Drug: Modified method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified method for generating null distributions of statistics pertaining to differences in G matrices
Study: 26362226
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D supplementation (800 mg calcium and 400 IU vitamin D daily for 6 months)
Study: 23680679
Drug: 8-week, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week, twice weekly exercise program
Study: 15854942
Drug: Preoperative methylene
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative methylene blue administration (2 mg/kg intravenously for more than 30 minutes, starting 1 hour before surgery)
Study: 12217418
Drug: Nociceptin (200pmol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nociceptin (200pmol) administered into tender non-dominant trapezius muscles
Study: 12217418
Drug: Nociceptin administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nociceptin administered into temporal muscle (open labeled design)
Study: 10731128
Drug: UVB phototherapy
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UVB phototherapy plus vehicle gel
Study: 8749244
Drug: Sumatriptan 6
Normalized name: sumatriptan 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 6 mg subcutaneously
Study: 8749244
Drug: Sumatriptan 12
Normalized name: sumatriptan 12 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 12 mg subcutaneously
Study: 19444560
Drug: Lidocaine 1.5
Normalized name: LIDOCAINE 1.5%/EPI 1:200000 INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 1.5 mg x kg(‐1) i.v. bolus 30 min before induction, followed by an infusion of 1.5 mg x kg(‐1) x h(‐1) until 1 h after surgery (n = 45)
Study: 17679315
Drug: Vagus nerve
Normalized name: SUS SCROFA VAGUS NERVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vagus nerve stimulation (VNS), details on dosage and duration not specified
Study: 12465163
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of supervised exercise program and group education
Study: 8126497
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (total lymphoid irradiation, TLI)
Study: 8126497
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (TLI)
Study: 30657995
Drug: MIRT (Multidisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIRT (Multidisciplinary Intensive Rehabilitation Treatment)
Study: 30657995
Drug: MIRT-AT (MIRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIRT-AT (MIRT with Aquatic Therapy)
Study: 26018633
Drug: Early invitation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invitation to food supplementation combined with multiple micronutrient supplements (MMS) including 30 mg iron and 400 μgm folic acid.
Study: 26018633
Drug: Usual invitation
Normalized name: BERGAMOT,IMITATION
DrugBank: Bergamot oil (DB14335)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual invitation to food supplementation combined with 60 mg iron and 400 μgm folic acid (UFe60F).
Study: 24334857
Drug: Autologous high‐molecular‐weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous high‐molecular‐weight plasma protein fraction therapy (AHPT)
Study: 24334857
Drug: Autologous plasma
Normalized name: AUTOLOGOUS CONDITIONED PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous plasma therapy (APT)
Study: 23102619
Drug: Resveratrol supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol supplementation (75 mg/day for 12 weeks)
Study: 17916183
Drug: Tadalafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (20 mg/every other day)
Study: 11952923
Drug: Group musical
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group musical therapy (15 sessions over 4 months)
Study: 11952923
Drug: Group musical
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group musical therapy
Study: 2354476
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (no thrombolytic therapy)
Study: 391176
Drug: Mepartricin (SPA‐S‐160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepartricin (SPA‐S‐160 enteric‐coated tablets)
Study: 27258938
Drug: Eugluc‐Hiinsu clamp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eugluc‐Hiinsu clamp with GIP infusion (1.5 pmol/kg/min)
Study: 27258938
Drug: Hyperglycemic‐hyperinsulinemic clamp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemic‐hyperinsulinemic clamp with GIP infusion (1.5 pmol/kg/min)
Study: 25024629
Drug: I.31 high
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.31 high dose (n = 28)
Study: 25024629
Drug: I.31 low
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.31 low dose (n = 27)
Study: 25024629
Drug: I.31 high
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.31 high dose
Study: 25024629
Drug: I.31 low
Approvals — FDA: no, EMA: no, PMDA: no
Description: I.31 low dose
Study: 22050270
Drug: Half-body fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-body fractional CO(2) laser therapy followed by NB‐UVB phototherapy
Study: 20920436
Drug: Inhaled FDKP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled FDKP (20 mg) in DNP subjects
Study: 20920436
Drug: Inhaled FDKP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled FDKP (20 mg) in subjects with normal renal function
Study: 20920436
Drug: Inhaled FDKP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled FDKP (20 mg) in healthy subjects
Study: 20920436
Drug: Inhaled FDKP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled FDKP (20 mg) in CLD subjects
Study: 20920436
Drug: Intravenous FDKP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous FDKP
Study: 20920436
Drug: Oral FDKP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral FDKP
Study: 8751847
Drug: Catheter-based radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter-based radiation therapies
Study: 25786369
Drug: AMG 416
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 416 (10 mg)
Study: 25786369
Drug: AMG 416
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 416 (5 mg)
Study: 22054204
Drug: MEL 308
Normalized name: Mel
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEL 308 nm + oral vitamin E
Study: 22054204
Drug: MEL 308
Normalized name: Mel
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEL 308 nm + 0.1% tacrolimus + oral vitamin E
Study: 22054204
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin E
Study: 19602250
Drug: Active acupuncture
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active acupuncture treatment (real acupuncture), 3 times per week for 12 sessions over 4 weeks.
Study: 19602250
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture treatment, 3 times per week for 12 sessions over 4 weeks.
Study: 19602250
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control group, no treatment during the 4 weeks, only recording symptoms in a daily diary.
Study: 17496402
Drug: Antibiotic lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic lock therapy using vancomycin and gentamycin
Study: 11907931
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) - transdermal estradiol 50 micrograms/day and 5 mg medroxyprogesterone acetate (MPA) for 2 years
Study: 7815242
Drug: High dosing
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosing (1,500 U lipase/kg body weight/meal, 750 U lipase/kg body weight/snack)
Study: 7815242
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing (500 U lipase/kg body weight/meal, 250 U lipase/kg body weight/snack)
Study: 7815242
Drug: High dosing
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosing in Group 1 (n = 7)
Study: 7815242
Drug: High dosing
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dosing in Group 2 (n = 14)
Study: 2900252
Drug: Bethanechol (5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bethanechol (5.0 mg s.c.)
Study: 2900252
Drug: Atropine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1.0 mg i.v.)
Study: 31197369
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation (NMES) treatment sessions for quadriceps muscles over 16 weeks (36 sessions)
Study: 23218533
Drug: Sublingual Zolpidem
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Zolpidem 10mg
Study: 23218533
Drug: Sublingual Zolpidem
Normalized name: zolpidem Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual Zolpidem 5mg
Study: 23218533
Drug: Oral Zolpidem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Zolpidem 10mg
Study: 16574034
Drug: Transdermal buprenorphine
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Transdermal buprenorphine (TDB) 35 mug/h patch
Study: 16574034
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl (DDTDF) 25 mug/h patch
Study: 1793781
Drug: Cisapride 30
Normalized name: cisapride 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride 30 mg t.d.s., by rectal administration
Study: 20491142
Drug: HyperHAES solution
Normalized name: Hyperhep B Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: HyperHAES solution (7.2% sodium chloride and hydroxyethyl starch 200/0.5)
Study: 20491142
Drug: 15% mannitol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% mannitol solution
Study: 20491142
Drug: 10% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% sodium chloride solution
Study: 17340596
Drug: Caries preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caries preventive agent
Study: 11719739
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (2 g) plus intravenous metoclopramide (20 mg)
Study: 11719739
Drug: Intravenous metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoclopramide (20 mg) plus placebo (intravenous saline solution)
Study: 11719739
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate plus metoclopramide
Study: 9167373
Drug: buprenorphine 0.2
Normalized name: buprenorphine 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: buprenorphine 0.2 mg sublingually two hours before dilatation
Study: 9167373
Drug: pentazocine 30
Normalized name: pentazocine 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: pentazocine 30 mg intravenously five minutes before dilatation
Study: 7701413
Drug: Rehabilitative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitative therapy (FKT)
Study: 7701413
Drug: FKT and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FKT and Ditropan (1 tablet 3 times daily for weeks therapy)
Study: 7701413
Drug: Traditional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional therapy with electric functional stimulation (SEF)
Study: 3295180
Drug: Fenoterol depot
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol depot (21 mg, single dose, p.o.)
Study: 3295180
Drug: Fenoterol (22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (22.5 mg, three doses, p.o.)
Study: 11062355
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg alendronate
Study: 1313762
Drug: 15 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/day rice bran
Study: 3019810
Drug: 15 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g/day wheat bran
Study: 1313762
Drug: 30 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g/day rice bran
Study: 1313762
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g wheat bran
Study: 1313762
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g rice bran
Study: 3933199
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg nightly for 3 years
Study: 8791968
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg nightly
Study: 30020088
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg orally 1 hour before surgery and at postoperative 12th and 24th hours
Study: 30020088
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg orally 1 hour before surgery, placebo at postoperative 12th hour, and duloxetine 60 mg at 24th hour
Study: 30020088
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules orally at all timepoints
Study: 22155172
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg rifaximin-EIR, given twice daily for 12 weeks